Practical challenges for functional validation of STAT1 gain of function genetic variants
Clinical and Experimental Immunology · 25.04.2023 · 212 (2) · 166-169
DOI: 10.1093/cei/uxad008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 01.02.2023. Verfasst von Adriana S Albuquerque und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunity and Transplantation, University College London, London, UK. Hauptthemen laut MEDLINE: Gain of Function Mutation, Candidiasis, Chronic Mucocutaneous. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health, UCLH Biomedical Research Centre.
Abstract (Originalsprache)
Wider application of next generation genetic sequencing (NGS) has significantly improved diagnosis for patients with inborn errors of immunity (IEI) and is increasingly a routine part of clinical practice [1, 2]. However, functional validation of genetic variants of unknown significance (VUS) remains a significant challenge for confirming definitive diagnoses, both due to inconsistent access to specialized testing and poor standardization of currently available assays [3]. The challenges are greater for conditions where clinical phenotype is not confirmatory due to heterogeneity or incomplete penetrance. STAT1 gain-of-function (GOF) immunodeficiency typically presents with chronic mucocutaneous candidiasis (CMC), with or without a combination of bacterial, viral or mycobacterial infections, along with other complications including bronchiectasis, autoimmunity and vascular abnormalities [4, 5]. Over 75 different individual genetic mutations have been described to confer gain of function in the STAT1 gene [6] and classically result in increased phosphorylation of STAT1 (pSTAT1) in immune cells, either at baseline or following cytokine stimulation [7]. Therefore, most immunology laboratories that offer validation assays for STAT1 VUS rely on comparing pSTAT1 levels between a potential index case and one or a group of healthy controls. However, levels of pSTAT1 at baseline and upregulation after cytokine stimulation vary considerably in the healthy population and overlap with levels observed in STAT1 GOF patients. In this study, we performed technically standardized flow cytometry assays using peripheral blood obtained from six patients with five different STAT1 VUS, identified through whole genome or targeted chip panel sequencing for suspected IEI (see Supplementary Table 1 and Methods). We compared these against 4 patients with known pathogenic GOF mutations in STAT1 and 16 healthy controls. A group of six patients with Common Variable Immunodeficiency (CVID) who had no pathogenic mutations identified in currently known IEI genes by NGS and no rare VUS in STAT1 were used as disease controls. Healthy control samples were taken on the same day as patient or disease control samples and assays performed in parallel. STAT1 VUS tested here were rare (allele frequency
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Immunity and Transplantation, University College London, London, UK.
- Department of Immunology, Royal Free London NHS Foundation Trust, London, UK.
- Department of Infectious Diseases, Royal London Hospital, Barts Health NHS Trust, London, UK.
- NIHR BioResource-Rare Disease Consortium, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
- Cambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
ORCID-Profile: Adriana S Albuquerque, Siobhan O Burns
Förderung
- NIGMS NIH HHS
- National Institutes of Health
- UCLH Biomedical Research Centre
- Medical Research Council
- Integrated Academic Training Scheme
- National Institute for Health Research
Zitieren
APA
Albuquerque, A. S., Maimaris, J., McKenna, A. J., Lambourne, J., Moreira, F., Workman, S., Megy, K., Simeoni, I., Lango Allen, H., NIHR BioResource-Rare Disease Consortium, Morris, E. C., & Burns, S. O. (2023). Practical challenges for functional validation of STAT1 gain of function genetic variants. Clinical and Experimental Immunology, 212(2), 166-169. https://doi.org/10.1093/cei/uxad008
Vancouver
Albuquerque AS, Maimaris J, McKenna AJ, Lambourne J, Moreira F, Workman S, et al. Practical challenges for functional validation of STAT1 gain of function genetic variants. Clinical and Experimental Immunology. 2023;212(2):166-169. doi:10.1093/cei/uxad008
BibTeX
@article{Albuquerque2023,
author = {Albuquerque, Adriana S and Maimaris, Jesmeen and McKenna, Alexander J and Lambourne, Jonathan and Moreira, Fernando and Workman, Sarita and Megy, Karyn and Simeoni, Ilenia and Lango Allen, Hana and NIHR BioResource-Rare Disease Consortium, NIHR BioResource-Rare Disease Consortium and Morris, Emma C and Burns, Siobhan O},
title = {Practical challenges for functional validation of STAT1 gain of function genetic variants},
journal = {Clinical and Experimental Immunology},
year = {2023},
volume = {212},
number = {2},
pages = {166--169},
doi = {10.1093/cei/uxad008}
}
EUVIMED